iShares MSCI South Africa ETF vs Revolution Medicines Inc. Common Stock — how do they compare? iShares MSCI South Africa ETF trades at $63.8 (market cap $455.34M), while Revolution Medicines Inc. Common Stock trades at $189.76 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 88.5× iShares MSCI South Africa ETF's market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Africa ETF for 70 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| EZA | RVMD | |
|---|---|---|
Market Cap | $455.34M | $40.32B |
Volume | 148,692 | 4,855,734 |
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $221.15 |
52-Week Low | $60.43 | $47.50 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | — | $37.02B |
Signals from Pluang's Aura AI — not financial advice
EZA trades at $63.8, up 2.42% today, but technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The stock faces resistance near $64 and support at $61. Recent news highlights a brief price surge above the 50-day moving average in September but ongoing macroeconomic pressures from South Africa's exposure to commodities and financials.
The outlook remains cautious due to global reflation and high capital costs weighing on EZA's holdings. Risks include commodity price volatility and interest rate sensitivity, while potential upside hinges on stabilization in South African markets. Investors should weigh the ETF's concentrated exposures against broader emerging market uncertainties.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →